The information provided on this site is intended only
for healthcare professionals (HCPs) in the United States.
Are you an HCP?
With THYQUIDITY, your patients or their caregivers can administer
the prescribed dose individualized to their TSH goal
Calibrated oral syringe provided by pharmacy.
*Assuming the strength of levothyroxine sodium prescribed daily is 88 mcg (4.4 mL). With two 100 mL bottles included in a package of THYQUIDITY, it would take a patient ~45 days to finish.2
T4: thyroxine; TSH: thyroid-stimulating hormone.
Microgram to milliliter conversion: mcg x 0.05 = mL or total mcg/20 = total mL of THYQUIDITY
Example: 60 mcg = 3.0 mL
†Starting dose depends on a variety of factors, including age, body weight, cardiovascular status, and concomitant medical conditions (including pregnancy), concomitant medications, coadministered food, and the specific nature of the condition being treated.
‡Evaluate the need for dose adjustments when regularly administering within one hour of certain foods that may affect THYQUIDITY absorption.
T4: thyroxine; TSH: thyroid-stimulating hormone.
Please see the Prescribing Information for additional guidelines for dosing in specific patient populations.
As a liquid, THYQUIDITY can help you meet patients’ individual
needs with flexible dosing adjustments1
Starting dose calculator for adults.
Levothyroxine dosing conversion by weight.
Starting dose calculator.
Levothyroxine tablet (mcg) to liquid (mL) conversion.
Healthy nonelderly adults (growth and puberty complete)
who have been hypothyroid for a short time (a few months)
Enter your patient’s
weight in pounds
Enter the desired
dose in micrograms
Recommended starting dose based on patient weight (1.6 mcg/kg).
Doses greater than 200 mcg per day are seldom required.
An inadequate response to daily doses of greater than 300 mcg per day is rare and may indicate poor compliance, malabsorption, drug interactions, or a combination of these factors.
View materials and programs available to patients taking THYQUIDITY
THYQUIDITY™ (levothyroxine sodium) oral solution is indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism.
THYQUIDITY is indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.
THYQUIDITY is not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients, as there are no clinical benefits and over-treatment with THYQUIDITY may induce hyperthyroidism.
THYQUIDITY is not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis.
WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS
Thyroid hormones, including THYQUIDITY, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects.
Please see full Prescribing Information including Boxed Warning.
You may report side effects to the FDA at 800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Vertice Specialty Group at 800-470-6233 or email at medinfo.vertice@apcerls.com.
References: 1. THYQUIDITY (levothyroxine sodium) oral solution [package insert]. New Providence, NJ: Vertice Specialty Group: 12/2020. 2. Data on file. Vertice Specialty Group. IQVIA 2020 Levothyroxine sodium class utilization by dose strength.
THYQUIDITY™ (levothyroxine sodium) oral solution is indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism.
THYQUIDITY is indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.
WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS
Thyroid hormones, including THYQUIDITY, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects.
The information provided on this site is intended only
for healthcare professionals (HCPs) in the United States.
Are you an HCP?
Coming Soon